“We are pleased to be working with Millipore,” said Proteome Sciences’ CEO Christopher Pearce. “We see this as a key step in the development of clinical tests for Alzheimer’s disease. These diagnostics will help scientists more precisely diagnose and monitor Alzheimer’s disease in its early stages, which are critically important.”

Proteome Sciences has established a strong portfolio of patent-protected blood biomarkers of Alzheimer’s disease working in collaboration with the Institute of Psychiatry (IoP) at King’s College London. A number of these biomarkers have been independently identified and their relationship to Alzheimer’s disease confirmed by researchers at GlaxoSmithKline.

“This collaboration will help us achieve our broader goal of advancing the study of neurobiology and neurodegenerative diseases,” said Jonathan DiVincenzo, President of Millipore’s Bioscience Division. “By expanding our portfolio of multiplex immunoassays targeting Alzheimer’s disease biomarkers, we will complement our portfolio of products for neuroscience that includes antibodies and ELISAs, neural stem cells, specialty media, and cell-based high content analysis kits. The development of a comprehensive multiplex Alzheimer’s panel will accelerate research and ultimately lead to better monitoring as a clinical tool.”

Millipore will acquire the exclusive right to develop and sell Luminex bead-based panels for research related to the study of Alzheimer’s disease and other cognitive function disorders. Proteome Sciences retains all rights to clinical applications of these biomarkers. Financial terms of the license agreement were not disclosed.

Alzheimer’s disease – Background

• 5.3 million Americans have Alzheimer’s disease
• A suspected new case is identified every 70 seconds in the US
• It is 5th leading cause of death in persons over the age of 65
• Economic costs exceed $142 bn in 2005 with $112 bn in direct medical costs
• 10-20% of persons over the age of 65 have mild cognitive impairment that may develop into Alzheimer’s disease

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit http://www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER^TM
Research. Development. Production.

About Proteome Sciences
Proteome Sciences is a leading biomarker CRO providing protein biomarker discovery, validation and assay development services. The Company’s MS Biomarker Assay system (MBA) uses its proprietary isobaric Tandem Mass Tags (TMT®) and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed in weeks and are suitable for screening 10's to 100's of candidate biomarkers in validation studies. Assays for validated biomarkers can be rapidly developed using the same isotope dilution mass spectrometry format, or can be transferred for immunoassay development.

The Company’s own research is focused on neurological and neurodegenerative conditions and it has discovered and patented blood biomarkers in stroke and brain damage as well as several cancers, solid organ transplant rejection and Alzheimer’s disease. Proteome Sciences is based in Cobham, UK with facilities in London and Frankfurt.

Millipore contact:

For Media: Karen Marinella Hall Director of Corporate Communications (978) 715-1567 karen_hall@millipore.com	For Investors: Joshua Young Director, Investor Relations (978) 715-1527 joshua_young@millipore.com
Proteome Sciences plc www.proteomics.com Christopher Pearce, Chief Executive Officer Dr. Ian Pike, Chief Business Officer James Malthouse, Finance Director Tel: +44 (0)1932 865065
Public Relations
IKON Associates Adrian Shaw Tel: +44 (0)1483 535102 Mobile: +44 (0)797 9900733 Email: adrian@ikonassociates.com	Coast Communications Matt Baldwin Tel: +44 (0)1233 503200 Mobile: +44 (0)7930 439739 Email: matt@coastcommunications.com
Nominated Adviser Noble Sam Reynolds Tel: +44 (0)20 7763 2243